Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalzanemdor - Sage Therapeutics

Next Previous
X
Search
Drug Profile

Dalzanemdor - Sage Therapeutics

Alternative Names: SAGE-718

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SAGE Therapeutics
  • Class Antidementias; Nootropics; Small molecules; Sterols
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Huntington's disease
  • Phase II Dementia; Mild cognitive impairment
  • Discontinued Encephalitis; Smith-Lemli-Opitz syndrome

Most Recent Events

  • 11 Jun 2024 Efficacy and adverse events data from the phase II SURVEYOR trial in Huntington's Disease released by Sage Therapeutics
  • 17 Apr 2024 Efficacy and adverse events data from a phase II PRECEDENT trial in Parkinson’s Disease released by Sage Therapeutics
  • 10 Apr 2024 Sage Therapeutics completes the phase II trial in Huntington's disease in USA (PO, Capsule) (NCT05358821)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top